Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Nuclear Medicine
Erschienen in: Annals of Nuclear Medicine 6/2013

01.07.2013 | Original Article

Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma

verfasst von: Ping-Wun Huang, Shih-Chung Tsai, Tsai-Yueh Luo, Chia-Hung Kao, Wan-Yu Lin

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

In our recent study, we developed a new radiopharmaceutical (Re-188 MN-16ET lipiodol) with encouraging results for the treatment of liver malignancy. In this study, we further evaluated the therapeutic efficacy of this radiopharmaceutical by measuring tumor response and survival times in rats with liver tumors after intra-hepatic arterial injection of Re-188 MN-16ET lipiodol.

Methods

Twelve male rats bearing hepatic tumors were divided into three groups. Group 1 received an intra-hepatic arterial injection of 18.5 MBq Re-188 MN-16ET lipiodol; Group 2 received lipiodol and Group 3 received normal saline. Tumor size was measured by liver sonography before injection, at 2, 4, and 8 weeks after injection. Survival time and response rate were calculated.

Results

All rats showed good response and survived over 60 days in Group 1 while all rats showed poor response in Group 2 and Group 3 with only 25 % of rats in Group 2 and none (0 %) in Group 3 survived over 60 days. The p value was 0.0067 between Group 1 and Group 3; 0.04 between Group 1 and Group 2; and 0.034 between Group 2 and Group 3.

Conclusion

Re-188 MN-16ET lipiodol has good potential for the treatment of hepatoma.
Literatur
1.
Jeong JM, Kim YJ, Lee YS, Ko JI, Son M, Lee DS, et al. Lipiodol solution of a lipophilic agent, 188Re-TDD, for the treatment of liver cancer. Nucl Med Biol. 2001;28:197–204.PubMedCrossRef
2.
Wang SJ, Lin WY, Chen MN, Hsieh BT, Shen LH, Tsai ZT, et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med. 1996;23:13–7.PubMedCrossRef
3.
Luo TY, Hsieh BT, Wang SJ, Lin WY, Lee TW, Shen LH, et al. Preparation and biodistribution of rhenium-188 ECD/lipiodol in rats following hepatic arterial injection. Nucl Med Biol. 2004;31:671–7.PubMedCrossRef
4.
Garin E, Denizot B, Noiret N, Lepareur N, Roux J, Moreau M, et al. 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl Med Commun. 2004;25:1007–13.PubMedCrossRef
5.
Sundram FX, Jeong JM, Zanzonico P, Bernal P. Trans-arterial rhenium-188 Lipiodol in the treatment of inoperable hepatocellular carcinoma. An IAEA-sponsored multi-centre phase I study. World J Nucl Med. 2002;1:5–11.
6.
Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys. 2007;69:1448–55.PubMedCrossRef
7.
Bernal P, Raoul JL, Stare J, Sereegotov E, Sundram FX, Kumar A, et al. International Atomic Energy Agency-Sponsored Multination Study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin Nucl Med. 2008;38:S40–5.PubMedCrossRef
8.
Lambert B, Bacher K, Defreyne L. Rhenium-188 based radiopharmaceuticals for treatment of liver tumors. Q J Nucl Med Mol Imaging. 2009;53:305–10.PubMed
9.
Lee YS, Jeong JM, Kim YJ, Chang YS, Lee HJ, Son M, et al. Development of acetylated HDD kit for preparation of 188Re-HDD/Lipiodol. Appl Radiat Isot. 2007;65:64–9.PubMedCrossRef
10.
Tang IC, Luo TY, Liu SW, Chan SH, Kung HC, Peng CL, et al. Synthesis and application of 188Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model. Nucl Med Biol. 2011;38:1043–52.PubMedCrossRef
11.
Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. Radiology. 1985;154:19–24.PubMed
12.
Raoul JL, Duvauferrier R, Bourguet P, Bretagne JF, Coornaert S, Darnault P, et al. Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol. J Radiol. 1986;67:797–801.PubMed
13.
Kobayashi H, Hidaka H, Kajiya Y, Tanoue P, Inoue H, Ikeda K, et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn. 1986;27:139–47.
14.
Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004;127:S218–24.PubMedCrossRef
15.
McCann JW, Larkin AM, Martino LJ, Eschelman DJ, Gonsalves CF, Brown DB. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? J Vasc Interv Radiol. 2012;23:661–7.PubMedCrossRef
Metadaten
Titel
Therapeutic efficacy of 188Re-MN-16ET lipiodol in an animal model of hepatocellular carcinoma
verfasst von
Ping-Wun Huang
Shih-Chung Tsai
Tsai-Yueh Luo
Chia-Hung Kao
Wan-Yu Lin
Publikationsdatum
01.07.2013
Verlag
Springer Japan
Erschienen in
Annals of Nuclear Medicine / Ausgabe 6/2013
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-013-0717-5

Weitere Artikel der Ausgabe 6/2013

Annals of Nuclear Medicine 6/2013 Zur Ausgabe

Original Article

The clinical value of tumor FDG uptake for predicting axillary lymph node metastasis in breast cancer with clinically negative axillary lymph nodes

Original Article

Underestimation of the ejection fraction using the quantitative gated SPECT for patients with myocardial hypertrophy

Original Article

Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation

Original Article

Imaging quality of F-18-FDG PET/CT in the inpatient versus outpatient setting

Original Article

The usefulness of 18F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with 18F-FDG PET/CT

Original Article

Scintigraphic comparison of renal ischemia–reperfusion injury models in rats: correlations with biochemical and histopathological findings